GCNT2 and polycystic ovary syndrome: Additionally, we will leverage AI-Driven Drug Design and computational biology approaches to develop low-toxicity, high-efficacy lead compound targeting GCNT2 and associated proteins, thereby paving the way for personalized and precision-based treatment strategies for PCOS patients.